LY2801653 clinical trial
- This topic has 52 replies, 14 voices, and was last updated 11 years ago by
.
-
Posts
-
Kris…. you deserve it. You should be the first to reap the benefits of this treatment. Rooting for you and wishing for the absolute best response. You have had to deal with so many side effects already and deserve a big break on this one.
And, dear Kris, charger….charger…charger. You may want to post on this site while waiting around at the facility.
Hugs
MarionI started the trial today. It was a long (can you say long?) day! 8 hours of not much… Blood work, wait….. Meet with onc…. Wait….. EKG and first day of pills….. Wait 4 hours UGH! And I forgot my chargers so my iPad died and my phone was about to!! Then another EKG and I was FINALLY free to go! Back tomorrow for 1-2 hours.
I will definitely keep everyone in the loop about this as I’m very hopeful we will ALL benefit from the results!! Just me first!
— I like to be first!!
I’m hoping for little to no side effects…..Hi Kris,
I found this about your study drug … Sounds exciting
http://www.wjgnet.com/1007-9327/full/v18/i21/2591.htm
Abstract # 2339: Prevalence of MET expression, activating mutations of KRAS and IDH1/2, and ROS1 fusions in cholangiocarcinoma patient tumor samples Exploring the c-MET pathway from a different direction is LY2801653, a small molecule, reversible oral ATP-competitive c-MET inhibitor. In addition to targeting MET, LY2801653 has been shown to inhibit the activity of ROS1 fusion proteins and MNK1 and MNK2, two signaling proteins downstream of KRAS. The study evaluated LY2801653 as a potential treatment of cholangiocarcinoma, a rare cancer that originates in the biliary tract epithelium and has a typically poor prognosis.
The study examined the prevalence of MET overexpression, activating single point mutations of KRAS and IDH1/2, and ROS1 gene fusions in intrahepatic and extrahepatic cholangiocarcinoma tumor tissues obtained from non-Asian (n=40) and Asian (n=60) patients. The majority of cholangiocarcinoma tumors expressed MET with approximately 50 percent of cases having strong staining (IHC score of 2+ or 3+). Overall, 25 percent of analyzed samples were positive for KRAS mutation, and mutations were more frequent in Asian patients. At approximately 60 percent of samples, G12D was the predominant mutation. For IDH1, the frequency of mutation was less than 10 percent overall, with R132C as the predominant mutation. IDH mutations were more frequent in non-Asian patients. There is no apparent correlation of MET expression with either KRAS or IDH1 mutations. IDH2 and ROS1 analyses are ongoing. The data suggest that inhibitors of receptor tyrosine kinases and their signaling pathways–such as LY2801653–may merit clinical evaluation in patients with cholangiocarcinoma.
Kris….so thrilled to know that another door may open for you in the fight against this cancer. A million good wishes are heading your way.
Hugs,
MarionGreat news indeed Kris and I hope that everything goes well and as planned. Everything will be crossed for you here and I look forward to hearing all about it.
Go Kris!!!!!
Kris, great news!! I hope it works as well for you as my new drug is working for my UC. You so deserve to be in the trial, you have certainly worked your A– off for it. I am so excited for you!
I have been approved for the clinical trial! Biopsy is scheduled for next week and I start the trial the following Monday, the 22nd. I can’t wait to see how well this new drug works!
I met with my new onc today. You like those words, Lainy, Marion, Pam???
Her suggestion: a phase 1 clinical trial using no chemo. This drug, as I understand it, is to work with the body to keep the disease stable. I can handle that, as I am not “sick” and was not looking forward to chemo. If we can keep it stable for four months or so, I can revisit radiation!!
I am so excited, but need to read all 27 or so pages.
It looks like there are side effects, but not as bad as chemo. And they will need to do an endoscopic biopsy thru my stomach wall to get to the new node to have a biopsy done. They are also using genetic testing to see how “we” handle the drug…
And if it doesn’t work, the new node is not in that dangerous an area where we need to worry immediately. If it doesn’t work, we go to the evil that we know: chemo. More on the trial as I learn more.
- The forum ‘Clinical Trials’ is closed to new topics and replies.